Mcrae Capital Management Inc. Sells 130 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Mcrae Capital Management Inc. decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,689 shares of the medical research company’s stock after selling 130 shares during the period. Thermo Fisher Scientific comprises 3.1% of Mcrae Capital Management Inc.’s holdings, making the stock its 13th largest holding. Mcrae Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $15,891,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the company. BDF Gestion bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $6,368,000. Aviance Capital Partners LLC raised its stake in Thermo Fisher Scientific by 20.9% during the first quarter. Aviance Capital Partners LLC now owns 13,043 shares of the medical research company’s stock worth $7,581,000 after acquiring an additional 2,251 shares in the last quarter. Lord Abbett & CO. LLC lifted its holdings in shares of Thermo Fisher Scientific by 1.9% in the first quarter. Lord Abbett & CO. LLC now owns 78,247 shares of the medical research company’s stock worth $45,478,000 after acquiring an additional 1,480 shares during the last quarter. Advisors Capital Management LLC grew its holdings in shares of Thermo Fisher Scientific by 5.8% during the 1st quarter. Advisors Capital Management LLC now owns 111,169 shares of the medical research company’s stock valued at $64,613,000 after purchasing an additional 6,089 shares during the last quarter. Finally, MV Capital Management Inc. lifted its stake in Thermo Fisher Scientific by 13.1% in the 1st quarter. MV Capital Management Inc. now owns 199 shares of the medical research company’s stock valued at $116,000 after purchasing an additional 23 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $76,420,473.36. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 6,300 shares of the stock in a transaction on Monday, July 29th. The stock was sold at an average price of $602.09, for a total value of $3,793,167.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $74,548,375.44. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Robert W. Baird decreased their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research note on Thursday. Bank of America upped their target price on Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a “buy” rating in a report on Monday, September 16th. TD Cowen boosted their price target on Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Raymond James raised their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Finally, UBS Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $649.33.

Thermo Fisher Scientific Stock Down 0.5 %

Shares of Thermo Fisher Scientific stock opened at $554.38 on Friday. The firm has a market cap of $211.77 billion, a price-to-earnings ratio of 34.39, a PEG ratio of 3.75 and a beta of 0.77. The stock’s 50-day moving average is $605.12 and its 200 day moving average is $584.00. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37. Thermo Fisher Scientific Inc. has a one year low of $420.21 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company’s quarterly revenue was up .2% on a year-over-year basis. During the same quarter last year, the firm posted $5.69 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.